This week's Houston innovators come from industries across the spectrum. Courtesy photos

This week in Houston is chock full of events from The Houston Innovation Summit, but before you get too swept away, check out these three innovators to know this week.

We have a life-long innovator whose passion has taken him from industry to industry, a construction specialist joining a growing Houston startup, and a man who let his personal struggles motivate him to find solutions.

Brad Rossacci, creative director at Accenture's Houston innovation hub

Brad Rossacci

Brad Rossacci, creative director for Accenture's Houston innovation hub, talks neuroscience, design, technology, and the upcoming Digital Fight Club on November 20 on this week's episode of the Houston Innovator's Podcast. Photo courtesy of Accenture

The guest on the Houston Innovators Podcast this week is Brad Rossacci, who's passion exudes from him in person — and podcast too. One of his recent passions? The Digital Fight Club, which is coming to Houston on November 20. The event puts two "fighters" on a stage with a referee to discuss various technology topics — cybersecurity, medicine, etc.

"I really fell in love with the approach [the event] takes," Rossacci says. "It takes this format that allows you to share ideas in a very short-form content kind of way." Read (and listen!) more.

Michael Matthews, industry principal at Data Gumbo

Michael Matthews

Data Gumbo has named the newest member of its executive team — and the newest industry it's looking to do business in. Photo courtesy of Data Gumbo

Michael Matthews was tapped to lead a brand new market that Houston blockchain startup, Data Gumbo, has announced an expansion into: Construction. The company uses blockchain to make it easier and faster to process industry contracts, payment, and more.

"The construction industry lags far behind other industries in both productivity improvement and technology adoption, resulting in billions of lost value," Matthews says in a news release. "The way companies come together to execute projects remains essentially the same despite technology's improvement and we have to make fundamental, disruptive changes to deliver more value." Read more.

Brigham Buhler, founder of Ways2Well

brigham buhler

Through his own patient journey, Brigham Buhler saw a need for Ways2Well to exist. Photo via ways2well.com

Sometimes, it's just too hard to find the answers you seek in health care. The waiting rooms, the parking, the forms — it's all a bit much only to leave empty handed. This was Brigham Buhler's experience, and finally, after months, he learned he had a hormone deficiency. Now, Buhler's company, Ways2Well, allows patients to quickly do a blood test at a lab and receive their results digitally.

"While most virtual health care providers focus on sick care — treating patients experiencing symptoms that indicate sickness — Ways2Well is focused on preventative health care," says Buhler. Read more.

Houston-based Ways2Well puts control back into the hands of patients. Photo via ways2well.com

This Houston virtual health care platform makes it easier to get answers

digital check up

As hard as he tried, Brigham Buhler couldn't achieve the weight-loss and fitness goals he'd set in his mid-20s. Plus, he constantly felt tired and stressed out. On top of that, Brigham's entire immediate family has diabetes, and he was exhibiting the warning signs.

Buhler's nutritionist recommended he get his hormones checked. It wound up taking three months to get an initial appointment with a urologist, who then recommended a comprehensive blood test.

The blood work revealed that he did, indeed, have a hormone deficiency. Subsequent hormone treatment, in addition to taking vitamins and supplements to combat various risk factors, got Buhler's endocrine system back on track.

Born out of that frustrating situation and spurred by his more than 15 years in the medical-device industry, Buhler launched Houston-based Ways2Well in 2018. Propelled by a virtual health care platform, the company envisions a better way to treat patients by challenging the traditional health care model.

"While most virtual health care providers focus on sick care — treating patients experiencing symptoms that indicate sickness — Ways2Well is focused on preventative health care," says Buhler, a graduate of the University of Houston.

Through his own patient journey, Brigham Buhler saw a need for Ways2Well to exist. Photo via ways2well.com

Here's how Ways2Well works.

A patient visits the company'swebsite to schedule a blood analysis at a Houston-area location of Quest Diagnostics. (Each year, Quest Diagnostics serves one-third of American adults and half of U.S. physicians and hospitals.)

Before the lab work, the patient discusses health concerns and wellness goals through a virtual appointment with a Ways2Well nurse practitioner.

Once the blood analysis is done, the nurse practitioner reviews the test results during a virtual appointment. The practitioner pinpoints underlying causes of chronic symptoms and potential risks for major conditions like heart disease, cancer, and diabetes. Those three ailments are the main drivers of the $3.5 trillion in annual health care costs racked up in the U.S. Ways2Well strives to reverse the symptoms of these and other chronic illnesses.

Finally, the nurse practitioner shares lifestyle or dietary changes that can reduce the likelihood of developing chronic diseases.

"Our online platform allows you to manage your health care journey from the convenience of your home or office, as long as you have access to a computer or phone and internet," Ways2Well says on its website.

Ways2Well charges nothing for a patient's initial 15-minute consultation. The blood analysis costs $299; Buhler says it goes well beyond what primary care doctors normally offer. The review of the blood analysis costs $120. Follow-up appointments cost $60 each. Neither Ways2Well nor ReviveRx accepts health insurance. However, an insurer might reimburse some out-of-pocket expenses.

The Ways2Well clinical team can prescribe medication, hormone therapy, prescription-grade vitamins and supplements, and other remedies through Ways2Well's partner pharmacy, ReviveRX. Ways2Well and ReviveRx occupy offices in the same building.

Typically, health care providers and pharmacies don't collaborate that closely on patient care. "Ways2Well is bridging that gap to offer better treatment to our patients," Buhler says.

Although ReviveRx is a full-service pharmacy, it doesn't operate like retail pharmacies such as Walgreens and CVS. Rather, patients are referred directly to ReviveRx by Ways2Well or Houston health care providers.

Today, Ways2Well focuses on the Houston market. But Buhler says the 12-employee, self-funded startup aims to expand to other Texas markets, such as Austin, Dallas-Fort Worth, and San Antonio.

"Because Ways2Well is a virtual health care provider that offers appointments via video conferences and leverages the Quest Diagnostics network for blood analysis, Ways2Well can treat patients from anywhere in Texas," he says. "Ultimately, the goal is to make Ways2Well available nationwide, with a team of clinical experts across the U.S."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice research breakthrough paves the way for advanced disease therapies

study up

Bioengineers at Rice University have developed a “new construction kit” for building custom sense-and-respond circuits in human cells, representing a major breakthrough in the field of synthetic biology, which could "revolutionize" autoimmune disease and cancer therapeutics.

In a study published in the journal Science, the team focused on phosphorylation, a cellular process in the body in which a phosphate group is added to a protein, signaling a response. In multicellular organisms, phosphorylation-based signaling can involve a multistage, or a cascading-like effect. Rice’s team set out to show that each cycle in a cascade can be treated as an elementary unit, meaning that they can be reassembled in new configurations to form entirely novel pathways linking cellular inputs and outputs.

Previous research on using phosphorylation-based signaling for therapeutic purposes has focused on re-engineering pathways.

“This opens up the signaling circuit design space dramatically,” Caleb Bashor, assistant professor of bioengineering and biosciences and corresponding author on the study, said in a news release. “It turns out, phosphorylation cycles are not just interconnected but interconnectable … Our design strategy enabled us to engineer synthetic phosphorylation circuits that are not only highly tunable but that can also function in parallel with cells’ own processes without impacting their viability or growth rate.”

Bashor is the deputy director for the Rice Synthetic Biology Institute, which launched last year.

The Rice lab's sense-and-respond cellular circuit design is also innovative because phosphorylation occurs rapidly. Thus, the new circuits could potentially be programmed to respond to physiological events in minutes, compared to other methods, which take hours to activate.

Rice’s team successfully tested the circuits for sensitivity and their ability to respond to external signals, such as inflammatory issues. The researchers then used the framework to engineer a cellular circuit that can detect certain factors, control autoimmune flare-ups and reduce immunotherapy-associated toxicity.

“This work brings us a whole lot closer to being able to build ‘smart cells’ that can detect signs of disease and immediately release customizable treatments in response,” Xiaoyu Yang, a graduate student in the Systems, Synthetic and Physical Biology Ph.D. program at Rice who is the lead author on the study, said in a news release.

Ajo-Franklin, a professor of biosciences, bioengineering, chemical and biomolecular engineering and a Cancer Prevention and Research Institute of Texas Scholar, added “the Bashor lab’s work vaults us forward to a new frontier — controlling mammalian cells’ immediate response to change.”

Greentown Labs names new CEO to lead pioneering climate tech incubator

Transition News

Houston and Boston climate tech incubator Greentown Labs has named Georgina Campbell Flatter as the organization’s incoming CEO.

Flatter will transition to Greentown from her role as co-founder and executive director of TomorrowNow.org, a global nonprofit that studies and connects next-generation weather and climate technologies with communities most affected by climate change.

“We are at a transformational moment in the energy transition, with an unprecedented opportunity to drive solutions in energy production, sustainability, and climate resilience,” Flatter said in a news release. “Greentown Labs is, and has always been, a home for entrepreneurs and a powerhouse of collaboration and innovation.”

Previously, Flatter worked to launch TomorrowNow out of tomorrow.io, a Boston-based AI-powered weather intelligence and satellite technology company. The organization secured millions in climate philanthropy from partners, including the Gates Foundation, which helped deliver cutting-edge climate solutions to millions of African farmers weekly.

Flatter also spent 10 years at the Massachusetts Institute of Technology (MIT), where she was a senior lecturer and led global initiatives at the intersection of technology and social impact. Her research work includes time at Langer Lab and Sun Catalytix, an MIT – ARPA-E-funded spin-out that focused on energy storage solutions inspired by natural photosynthesis. Flatter is also an Acumen Rockefeller Global Food Systems Fellow and was closely involved with Greentown Labs when it was founded in Boston in 2011, according to the release.

“It’s rare to find an individual who has impressive climate and energy expertise along with nonprofit and entrepreneurial leadership—we’re fortunate Georgie brings all of this and more to Greentown Labs,” Bobby Tudor, Greentown Labs Board Chair and Chairman of the Houston Energy Transition Initiative, said in a news release.

Flatter will collaborate with Kevin Dutt, Greentown’s Interim CEO, and also continue to serve on Greentown’s Board of Directors, which was recently announced in December and contributed to a successful $4 million funding round. She’s also slated to speak at CERAWeek next month.

“In this next chapter, I’m excited to build on our entrepreneurial roots and the strength of our ever-growing communities in Boston and Houston,” Flatter added in a news release. “Together, we will unite entrepreneurs, partners, and resources to tackle frontier challenges and scale breakthrough technologies.”

Greentown also named Naheed Malik its new chief financial officer last month. The announcements come after Greentown’s former CEO and president, Kevin Knobloch, announced that he would step down in July 2024 after less than a year in the role.

---

This article originally appeared on our sister site, EnergyCapital.

Houston firm invests $150M in leading 'lab on a chip' medical diagnostics co.

fresh funds

Houston-based health technology investment firm Hamershlag Private Capital Management Limited (HPCM) announced a $150.15 million venture investment in Patho Care LLC.

Patho Care is a “lab on a chip” medical diagnostics company known for its noninvasive point-of-care testing platforms, such as its Raman spectroscopy-based platform.

Its digital point-of-care testing devices are programmable, mobile, and reusable and can detect current or future respiratory bacterial or viral infections. The company says the technology is more cost-effective and provides results faster than traditional diagnostic methods.

“Patho Care LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries,” L. Mychal Jefferson, Chairman of Hamershlag, said in a news release.

The transaction was structured as an acquisition and recapitalization using newly issued common stock and cash, which will work through a newly formed entity, PathoCare Holdings Inc. The deal will also facilitate the repayment of Patho Care LLC's existing financial obligations and settle Patho Care’s outstanding notes, helping ensure the company’s financial readiness, according to the release.

The investment will help Patho Care LLC improve operational efficiencies, broaden its service offerings and continue to innovate in the diagnostic testing space. The companies hope the collaboration will help “unlock new growth opportunities while maintaining the company’s legacy of excellence in an emerging technology,” according to a news release.

“Our commitment to delivering transformative value through innovative investments underscores our confidence in Patho Care’s vision and capabilities,” Jefferson added.